Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by CenterBook Partners LP

CenterBook Partners LP lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,246 shares of the biopharmaceutical company’s stock after selling 26,977 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.1% of CenterBook Partners LP’s portfolio, making the stock its 13th biggest holding. CenterBook Partners LP’s holdings in Regeneron Pharmaceuticals were worth $23,346,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. TD Private Client Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. CYBER HORNET ETFs LLC lifted its holdings in Regeneron Pharmaceuticals by 6.0% in the fourth quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 17 shares during the period. Meyer Handelman Co. lifted its holdings in Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after purchasing an additional 18 shares during the period. Finally, Gateway Investment Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 4.3% in the fourth quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 19 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $635.45 on Monday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $706.93 and its two-hundred day moving average price is $742.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $485.00 and a 52 week high of $821.11. The stock has a market cap of $67.18 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the business earned $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Royal Bank Of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a report on Monday, May 18th. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Finally, Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.